FDA U.S. Agent for drug establishments in China
A drug establishment in China that exports to the United States must register with FDA and name a U.S. Agent located in the U.S. (21 CFR 207.69). In the 12 months from 2025-10 to 2026-09, FDA refused 2,749 import lines from China, and 85 FDA import alerts list firms from China.
FDA data for China
Figures from FDA public data, retrieved 2026-10-21. Recall counts are by the recalling firm's country.
Import refusals, 2025-10 to 2026-09
| Refused import lines | 2,749 |
| Refusals citing registration or listing problems | NOT LISTED-118 · 388 FRNMFGREG-3280 · 279 |
Most common refusal charges
| Code | Count |
|---|---|
| TP NO PMTA-3842 This article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act because it is a tobacco product that FDA has found to be adulterated under section 902(6)(A) of the FD&C … | 415 |
| MELAMINE-3421 The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to bear or contain a food additive, namely melamine and/or a melamine analog, that is unsafe within the… | 401 |
| TP NO SE-3843 This article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act because it is a tobacco product that FDA has found to be misbranded under section 903(a)(6) of the FD&C A… | 396 |
| NOT LISTED-118 The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information… | 388 |
| FRNMFGREG-3280 The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, i… | 279 |
Import alerts listing China firms
Import alerts that list at least one firm in China: 85. Recently updated:
- Import Alert 16-129: Detention Without Physical Examination of Seafood Products Due to Nitrofurans
- Import Alert 16-39: Detention Without Physical Examination of Ready-to-Eat Seafood for Listeria monocytogenes
- Import Alert 45-02: Detention Without Physical Examination and Guidance of Foods Containing Illegal and/or Undeclared Colors.
- Import Alert 45-06: Detention without Physical Examination of Stevia Leaves, Crude Extracts of Stevia Leaves and foods Containing Stevia Leaves and/or Stevia Extracts
- Import Alert 99-05: Detention Without Physical Examination Of Raw Agricultural Products for Pesticides
- Import Alert 99-08: Detention without Physical Examination of Processed Human and Animal Foods for Pesticides
Recalls by China firms, last 5 years
33 (Class II: 22, Class I: 11)
Recent recall reasons:
- 2026-04 This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing fa…
- 2026-03 CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
- 2025-10 cGMP Deviations
What the rule requires
A foreign establishment that manufactures, repacks, relabels or salvages a drug imported or offered for import into the United States must register with FDA electronically, list its drugs, and identify a U.S. Agent who lives or has a place of business in the U.S. Registration is renewed each year between October 1 and December 31.
- Foreign manufacturers of finished human and animal drugs, including OTC products and hand sanitizers
- Foreign API manufacturers, repackers and relabelers whose products are imported into the U.S.
Deadlines
- Register within 5 calendar days after beginning operations (21 CFR 207.21)
- Renew annually between October 1 and December 31 (21 CFR 207.29)
- Update drug listings each June and December, or certify no changes
Steps
- Get a DUNS number for the establishment
- Request a labeler code if you will list products under your own name
- Prepare Structured Product Labeling (SPL) files for registration and listing
- Submit through FDA's Electronic Submissions Gateway or CDER Direct
- The U.S. Agent is named in the registration and FDA contacts them to confirm
Common mistakes
- Submitting SPL with a DUNS whose address does not match
- Missing the year-end listing certification
- Assuming registration or an NDC number means FDA approved the drug. It does not
How US Agent Desk helps
We serve as your U.S. Agent, prepare the registration data in your language for your company's officer to submit, confirm the designation when FDA asks, and check FDA's public records for your company every morning. Prices start at $990 per year.
Check if you need a U.S. Agent See prices
Independent private service. Not affiliated with the U.S. FDA. Not legal advice.